PG — The Procter & Gamble Company

The market is neither euphoric nor panicked on PG. As of 2026-09-13 the shares had returned -0.8% over one week, +0.83% over one month, -2.9% over three months and -3.57% over six months, with RSI (14) at 49.89 - dead center. Price sat +0.33% above the 20-day SMA but -0.78% below the 50-day and -1.5% below the 200-day, i.e. a stock quietly drifting sideways-to-lower rather than trending. The July 29, 2026 Q4/FY26 print (filed August 4) was mixed: revenue roughly inline and flat, GAAP diluted EPS of $1.26 (management-cited core EPS of ~$1.43), full-year organic growth of only ~1%, and YoY operating-margin compression in every quarter of FY26. Offsetting that, the CFO used the September 2026 Barclays conference to argue underlying U.S. consumption was running ~2.5% and that the share of major U.S. customers holding or growing share rebounded to roughly 50% from under 10% earlier in the year. Sell-side is a moderate Buy (28 buy / 24 hold / 1 sell) with a $157.78 consensus target, but only ~8-9% implied upside - a target that says 'fairly valued, modest total return,' not 'mispriced.'

Decelerating on the top line and compressing on margins - this is a genuine multi-quarter trend, not a one-quarter blip. Revenue growth by quarter: Q1 FY26 (Sep-25) +2.99% YoY, Q2 FY26 (Dec-25) +1.49%, Q3 FY26 (Mar-26) +7.38% (flattered by an unusually weak prior-year Q3 comparison of $19.78B), Q4 FY26 (Jun-26) +1.50%. Full fiscal 2026 revenue of $87.03B was up ~3.3% reported over FY25's $84.28B, but the exit rate is low-single-digit and management guides FY27 organic growth of only 1-3%. Operating margin fell YoY in all four FY26 quarters: Q1 -51bps (26.16% vs 26.67%), Q2 -208bps (24.16% vs 26.24%), Q3 -150bps (21.55% vs 23.05%), Q4 -222bps (18.63% vs 20.85%). Gross margin tells the same story - 52.39% in Q2 FY25 down to 48.50% in Q4 FY26, a nearly 390bp compression over six quarters, consistent with lower pricing realization plus commodity/energy and freight pressure. Earnings confirm the slowdown: FY25 EPS of $6.51 grew ~8.1% over FY24's $6.02, but FY26 EPS of $6.62 grew only ~1.7% YoY. The one clearly improving line is cash: FY26 free cash flow of $15.91B rose ~13% over FY25's $14.04B (though still below FY24's $17.77B), and the accruals ratio of -2.29% as of 2026-06-30 means cash generation is running ahead of reported net income - a healthy, conservative quality signal. Bottom line: revenue is not collapsing but the growth engine has downshifted from price-led to volume-dependent, and margin, not demand, is the real problem.

Fair, leaning mildly cheap versus its own history but not cheap in absolute terms. As of 2026-09-13 the trailing P/E was 21.52x versus a 24.18x five-year average - roughly an 11% discount - and P/S was 3.968x versus a 4.42x five-year average. On next-FY consensus EPS of $6.976 the forward P/E is 20.8x, which is defensible for a business with 50.2% gross margins, 22.7% operating margins, 15.7% ROIC, 29.5% ROE and a 2.91% dividend yield - but not screamingly cheap for ~1% organic growth. Note the reported PEG of 20.54 is essentially meaningless here: it is a mechanical artifact of near-zero trailing earnings growth being divided into a 21x multiple, not a signal that PG is 20x overvalued on growth. EV/EBITDA of 17.7x and P/B of 6.48x are on the high side, though P/B is a poor metric for an asset-light brand company whose Tide/Gillette/Pampers intangibles sit far below fair value on the books. Net read: you are paying a fair multiple for a fair-growth staple, with the dividend doing most of the work until growth reaccelerates.

At $145.27, PG is priced for roughly what it is currently delivering - high-single-digit total return (2.9% dividend plus low-single-digit earnings growth) - and not for the ~5% EPS growth embedded in the $6.976 next-FY consensus estimate. That estimate requires margin stabilization, which has not yet happened for four straight quarters. So the setup is asymmetric in a mild way: if commodity and freight costs ease (management's guidance assumes Brent near $90/bbl, so any easing is upside), the multiple can hold ~22x and EPS can grow ~5%, supporting the mid-$150s. If gross margin compresses for a fifth consecutive quarter, the stock drifts toward the 20x floor (roughly $140) with the 52-week low of $137.62 as the technical backstop. In other words, the stock is not 'pricing in growth that hasn't shown up' - if anything it is pricing in a flat-to-slow FY27, which is why downside from here looks more limited than upside. The Q1 FY27 print in late October 2026 is the deciding datapoint.

Range-bound with a slight negative tilt, no timing edge. As of 2026-09-13, RSI (14) stood at 49.89 - neither overbought nor oversold, and notably directionless. The stock was +0.33% versus its 20-day SMA (barely above), -0.78% versus its 50-day SMA, and -1.5% versus its 200-day SMA, a configuration that says 'basing below the long-term trend line,' not 'breakdown' and not 'breakout.' Return profile confirms it: +0.83% over one month, -2.9% over three, -3.57% over six. Price sits in the lower third of the $137.62-$167.25 52-week range. Implication for entry timing: there is no technical urgency to buy today, but there is also no technical alarm - the $137.62 low is the level that matters, the 200-day SMA (~$147-148 by inference) is the first hurdle to reclaim, and a neutral RSI in a low-beta (0.377) name means this is a 'scale in, collect the dividend' chart, not a momentum chart.

• Commodity and energy costs: management's FY27 guidance bakes in a Brent crude assumption near $90/bbl. Freight and transport normalization is the single biggest swing factor for gross margin - any easing flows almost directly to the 48.5% gross margin line that has been the weak spot.
• Cumulative consumer inflation fatigue: staples demand is resilient, but volumes are muted as shoppers stretch budgets and trade down in premium tiers. PG is caught between needing price to protect margin and needing volume to grow revenue.
• Interest rates and sector rotation: with a 0.377 beta and a 2.91% dividend yield, PG trades as a bond proxy. Its relative attractiveness versus Treasuries - and versus higher-beta cyclicals on a rotation - drives multiple expansion or contraction more than any single quarter of earnings.
• Foreign exchange and international mix: roughly half of revenue is non-U.S., making reported results hostage to dollar strength. Latin America and Greater China (several quarters of sequential growth) are relative tailwinds the U.S. market lacks.
• Tariffs and trade policy: input-cost volatility and any change in tariff regimes on imported raw materials or finished goods would compound an already-strained gross margin.

• Q1 FY27 earnings, expected late October 2026: the first hard read on whether organic sales land in management's 1-3% guidance range and, more importantly, whether gross and operating margin stop compressing after four consecutive YoY declines.
• Commodity and freight cost relief: if Brent and transport costs ease in the back half of FY27 as management hopes, the margin recovery is the fastest path to the ~5% EPS growth analysts are modeling.
• Share and volume recovery: management reported the share of major U.S. customers holding or growing share rebounded from under 10% to roughly 50% exiting Q4 FY26 - if that holds, it validates the ~2.5% underlying U.S. consumption the CFO cited versus the flat reported number.
• Premiumization pipeline: Tide Evo, Oral-B iO, and lifestyle collaborations (Febreze x Dunkin') are mix-accretive if they land; failure to move mix leaves PG dependent on price, which is exactly what decelerated in FY26.
• Dividend increase and capital return: PG's long streak of annual dividend raises, typically announced in April, remains a support for the income-oriented holder base.

• Margin compression becoming structural rather than cyclical: operating margin fell YoY in every FY26 quarter (-51bps, -208bps, -150bps, -222bps) and gross margin shed ~390bps over six quarters. A fifth straight down quarter would force consensus EPS of $6.976 lower and likely take the multiple to 20x or below.
• Volume stagnation and private-label trade-down: with growth now dependent on volume rather than price, a cautious consumer permanently shifting toward store brands stalls the top line at ~1% for longer than the market expects.
• Valuation gives no real cushion: at 20.8x forward earnings for ~1% organic growth, PG is not a deep-value stock. If growth stays at 1%, the multiple can compress toward the high teens, which is roughly the $137-140 area.
• Balance-sheet optics: current ratio of 0.677 and quick ratio of 0.466 reflect PG's deliberate negative-working-capital model, but with only $9.94B of cash against $38.69B of current liabilities, a sharp input-cost spike would have to be funded from cash flow rather than the balance sheet.
• FX and geopolitical exposure: with roughly half of sales outside the U.S., a stronger dollar or trade/tariff disruption hits reported revenue and margin simultaneously.

PG is a genuinely high-quality business - 50%+ gross margins, 22.7% operating margins, 15.7% ROIC, ~$16B of annual free cash flow, a 2.91% dividend, and a 0.377 beta - but it is in a low-growth, margin-compressing phase that the cheap-versus-its-own-history multiple (21.5x vs. 24.18x five-year average) only partly compensates for. At $145.27 on 2026-09-13 you are paying a fair price for a fair business: the dividend and buyback will grind out a mid-single-digit total return, but there is no obvious catalyst for re-rating until gross margin stops falling, and the Q1 FY27 print in late October is the gate. This is a reasonable hold for an income-oriented investor and a mediocre fresh-money buy; the risk/reward is balanced rather than skewed.

I applied a 22.0x justified P/E - a deliberate discount to PG's 24.18x five-year average and modestly above its 20.8x forward multiple, reflecting wide-moat quality but decelerated ~1% organic growth - to next-FY consensus EPS of $6.976, giving $153.5. Two cross-checks bracket that number: a Gordon-growth DCF on TTM free cash flow per share of $6.69 at an 8.5% cost of equity and 4% perpetual growth yields ~$155, and a dividend discount on the ~$4.23 annual payout at 5% growth and an 8% required return yields ~$148. The $153.50 figure sits in the middle of all three methods and implies roughly 5-6% upside from the 2026-09-13 price of $145.27, deliberately below the $157.78 sell-side consensus because I am not yet willing to underwrite the ~5% FY27 EPS growth that consensus assumes before margin stabilization is actually visible.